课题基金 / 基金详情

项目摘要

项目成果

PETER A JONES的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Bladder cancer is common in the United States and is bnmkjrelatively understudied relative to its public health implications. This project seeks to understand how the epigenetic silencing of apoptotic genes by abnormal methylation of cytosine residues occurs as a function of age and carcinogenesis. We have discovered that we can use the quantitative MethyLight high throughput platform to detect DNA methylation changes in urine sediments, which gives us unique opportunities to study cancer evolution and progression in a longitudinal fashion using a noninvasive sampling technique. We wish to take advantage of the availability of urine sediments to translate our basic science discoveries into strategies which can assist in the identification of recurrent tumors. Since recurrence is a common feature of superficial bladder cancer, the achievements of these goals would have profound impact on the patient's quality of life. To achieve these goals we will accomplish the following specific aims. First, we will complete the development of a marker panel of CpG islands located upstream and just downstream of the transcription start sites of apoptotic genes and verify that methylation observed in urine sediments corresponds with methylation in the primary tumors. Secondly, we will take advantage of the urine sediment system to ascertain how DNA methylation patterns evolve in the urinary bladder as a function of aging. Thirdly, we will conduct consecutive studies on patients who have been surgically treated for either superficial or invasive bladder cancer to determine whether the methylation patterns present at the time of initial surgical excision reappear in the urine sediments before the recurrent tumors can be detected by conventional means. Thus, the achievement of these three specific aims will allow us not only to understand the epigenetics of bladder cancer but also use these fundamental discoveries to better the lives of patients with this disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Cancer Epigenetics Training (CET) Program
  • 批准号:
    10646461
  • 项目类别:
  • 资助金额:
    $47.04万
  • 财政年份:
    2021
  • 负责人:
    PETER A JONES
  • 依托单位:
Cancer Epigenetics Training (CET) Program
  • 批准号:
    10269565
  • 项目类别:
  • 资助金额:
    $14.39万
  • 财政年份:
    2021
  • 负责人:
    PETER A JONES
  • 依托单位:
Cancer Epigenetics Training (CET) Program
  • 批准号:
    10445044
  • 项目类别:
  • 资助金额:
    $30.65万
  • 财政年份:
    2021
  • 负责人:
    PETER A JONES
  • 依托单位:
Targeting DNA Methylation and the Cancer Epigenome
  • 批准号:
    10541829
  • 项目类别:
  • 资助金额:
    $109.5万
  • 财政年份:
    2017
  • 负责人:
    PETER A JONES
  • 依托单位:
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
  • 批准号:
    2025JJ70209
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
    雷芬芳
  • 依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    万荣
  • 依托单位: